Monday, December 10 - Scientific Presentations

ASH 2001

A Randomized Trail of Fludarabine and Mitoxantrone Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma Acute Myeloid Leukemia in Adolescents and Young Adults (AYAs): A Comparison of Outcomes Between Patients Treated on Childhood or Adult Protocols Air Travel, Prothrombotic Mutations and Venous Thrombosis: The MEGA Study CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL) CHOP Alone Compared to CHOP Plus Radiotherapy for Early Stage Aggressive Non-Hodgkin's Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial. Cytotoxicity of Mevastatin and Other Cholesterol Modulators in Acute Myeloid Leukemia Early Restaging Positron Emmision Tomography (PET) with 18F-Fluorodeoxyglucose (18FDG)Predicts Outcome in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL) Final Report of E1484: CHOP vs CHOP + Radiotherapy (RT) for Limited Stage Diffuse Aggressive Lymphoma Gastric MALT Lymphomas Prospective LY03 Randomized Cooperative Trial: Preliminary Results of the Molecular Follow-up High Levels of Soluble CD20 (sCD20) in patients with Non-Hodgkin's Lymphoma (NHL): Correlation with Clinical Behavior and Contrast with Patients with Hodgkin's Disease (HD) Multiple Resistance Mechanisms Identified through Studies of Cell Lines Derived from Chronic Myelogenous Leukemia Patients Progressing on STI-571 Therapy Requestioning the Role of Prolonged Maintenance Chemotherapy in AML: Randomized Trial by the German AML Cooperative Group Updated. t(11;18) Is a marker for All Stage Gastric MALT Lymphomas That Will Not Respond o H. Pylori Eradication The Combination of Low D-Dimer Concentration and Non-High Clinical Probability Score is a Safe Strategy to Exclude Deep Venous Thrombosis Thrive I: Efficacy and Tolerability of the Novel, Oral Direct Thrombin Inhibitor Ximelagatran Compared with Standard Therapy for the Treatment of Acute Deep Venous Thrombosis


Click on any of these terms for more related articles


Roasted Vegetables and Farro
by Carolyn Vachani, MSN, RN, AOCN
September 30, 2013

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

ASH: Most Cancer-Related Clots Occur in Outpatients

Dec 14, 2011

Of the venous thromboembolism cases in patients with cancer, 78.3 percent occur in outpatients

Diagnosis of any cancer for up to 10 years does not differ between statin and non-statin users

Nov 18, 2010

Diagnosis of any cancer for up to 10 years does not differ between statin and non-statin users

ASH: Somatic Mutations ID'd in Chronic Lymphocytic Leukemia

Dec 13, 2011

Mutations identified in nine genes, including SF3B1, with no prior established role in CLL

From the National Cancer Institute